DHA-paclitaxel is primarily utilized in the field of oncology as a chemotherapeutic agent. It is designed to enhance the delivery and efficacy of paclitaxel, a well-known chemotherapy drug, by conjugating it with docosahexaenoic acid (DHA). This conjugation aims to improve the drug's solubility and targetability towards cancer cells, thereby reducing systemic toxicity and increasing therapeutic outcomes. In clinical settings, DHA-paclitaxel is used to treat various types of cancers, including breast, ovarian, and lung cancers. Its mechanism of action involves disrupting the normal function of microtubules during cell division, leading to the inhibition of cancer cell proliferation and eventual cell death. The DHA component is believed to facilitate the preferential uptake of the drug by tumor cells, which often have a higher demand for fatty acids. Moreover, DHA-paclitaxel is being investigated in combination therapies, where it is used alongside other chemotherapeutic agents or radiation therapy to enhance overall treatment efficacy. Research is also ongoing to explore its potential in overcoming drug resistance, a common challenge in cancer treatment. Overall, DHA-paclitaxel represents a promising advancement in chemotherapy, offering the potential for more targeted and less toxic cancer treatment options.